Should the federal government require Medicare to cover the cost of weight-loss drugs like Ozempic?
Under a 2003 law, the federal government is currently banned from paying for weight-loss medications, classifying them as "lifestyle" drugs similar to hair growth treatments. The explosion of new GLP-1 agonists like Ozempic and Wegovy has challenged this, as these drugs significantly reduce weight and health risks but cost upwards of $1,000 a month. Supporters of the Treat and Reduce Obesity Act argue coverage is a moral imperative that will eventually lower costs by reducing rates of stroke, diabetes, and heart disease. Opponents argue the astronomical upfront cost of providing these drugs to the 40% of seniors who are obese would necessitate massive tax hikes or premium increases.
Toggle voterbase
Statistics are shown for this demographic
Political party
County
Answer Overview
Response rates from 7.8k America voters.
Historical Support
Trend of support over time for each answer from 7.8k America voters.
Loading data...
Loading chart...
Historical Importance
Trend of how important this issue is for 7.8k America voters.
Loading data...
Loading chart...
Other Popular Answers
Unique answers from America voters whose views went beyond the provided options.
@BBCMLDL 4mos4MO
@SThunstrom11 5 days5D
@BF47ZS46 days6D
@BF476BF7 days7D
@BF3CWY91wk1W
@BluSani 1wk1W
@BF2G94C2wks2W
@BF2FY852wks2W
Popular Conversations
Join in on the most popular conversations.
About This Data
Based on 7.8k responses to this question.
These results come from iSideWith's ongoing political issues survey. We collect over a million responses per day, filter out duplicate and multiple submissions, and break the results down by political party, ideology, age, state, and census demographics (income, race, education, household).
iSideWith is non-partisan — we don't advocate for any party, candidate, or position. We report what the public tells us.
Cite Or Embed This Poll
Writing about this issue? Use the live data and link back to the full results.





